How medical grade honey is sterilised — gamma, e-beam and what survives

Raw honey carries a small but non-zero bioburden — mostly Bacillus and Clostridium spores that arrive on the bee, in the pollen, or on hive equipment. The numbers are low (typically < 10² CFU/g for well-handled honey) but for a wound dressing, an ophthalmic product or any sterile single-use device the bioburden has to come down to a sterility assurance level of 10⁻⁶.

Why heat is not an option

Pasteurisation works for jam and milk because both tolerate temperature. Honey does not. Above about 40 °C, hydrogen peroxide activity drops, hydroxymethylfurfural (HMF) climbs, and consumer-facing quality markers degrade fast. Above 60 °C, even MGO begins to react with amino acids and disappear. Autoclave-style steam sterilisation is therefore off the table.

The standards stack

Medical-grade honey is manufactured under ISO 13485 quality management, with the sterilisation process validated per ISO 11137 for radiation (gamma or electron beam) or ISO 11135 for ethylene oxide. The dressing itself sits inside a finished medical device that has its own ISO 10993 biocompatibility file. Three layers of standards, each with its own audit trail.

Gamma irradiation — the workhorse

Around 90% of medical-grade honey worldwide is sterilised by gamma irradiation, almost always cobalt-60 at a target dose of 25 kGy. The dose is set by ISO 11137 Method 1 or VDmax₂₅, both of which use the measured pre-sterilisation bioburden to prove that 25 kGy gives 10⁻⁶ SAL with margin to spare.

Gamma is attractive for honey for three reasons: it works through the primary packaging (no aseptic transfer required), it works at ambient temperature, and it works in single-pass production. Crates of finished, sealed product enter the irradiator on a conveyor and leave sterile.

Electron beam — the alternative

E-beam delivers the same 25 kGy in seconds rather than hours. It is increasingly used for thin-profile honey-impregnated dressings where the dose distribution can be controlled tightly. The chemistry of the sterilised honey is indistinguishable from gamma-treated product.

Activity retention

Industry batch-release data for Manuka medical dressings show MGO retention of ≥ 95% post-25-kGy across normal cycle variation. The peroxide component of any non-Manuka honey takes a larger hit because the enzymes that generate it are damaged by radiation. For a pure Manuka product that distinction does not matter; for a multifloral medical honey the dossier has to account for the loss.

What buyers should ask for

• Sterilisation method and target dose (gamma 25 kGy is the default).
• The ISO 11137 dose-setting method used (Method 1 or VDmax₂₅).
• Pre- and post-sterilisation MGO/DHA on every lot.
• Sterility test results or parametric release evidence.
• The bioburden trend across the last 12 months — a rising trend is a sourcing problem, not a sterilisation problem.